Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 0.41 |
| ▸ | MET | P08581 | 16/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23749476 | 0.92 | MET (0.47) | AXLMETL3MBTL1 | |
| SCHEMBL23771043 | 0.90 | MET (0.39) | AXLMETMERTKL3MBTL1 | |
| SCHEMBL14969174 | 0.88 | KDM4E (0.43) | AXLMETMERTKL3MBTL1GSK3A | |
| SCHEMBL29814160 | 0.87 | AXL (0.41) | AXLMETMERTKGSK3AGSK3B | |
| SCHEMBL23749414 | 0.85 | MET (0.46) | AXLMET | |
| SCHEMBL23749366 | 0.85 | MET (0.49) | AXLMET | |
| SCHEMBL24066364 | 0.84 | MET (0.48) | AXLMETL3MBTL1 | |
| SCHEMBL22511482 | 0.82 | MET (0.49) | AXLMETL3MBTL1 | |
| SCHEMBL22511514 | 0.82 | MET (0.46) | AXLMETMERTKL3MBTL1 | |
| SCHEMBL23071265 | 0.82 | LMNA (0.46) | AXLMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| CN-111196814-B | Aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
| CN-111196814-A | Aromatic ring connecting dioxane quinazoline or quinoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2020-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | MERTK, AXL, TYRO3 | AXL 2/4885MET 14/4885MERTK 1/4885 |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | MERTK, AXL, TYRO3 | AXL 2/4885MET 12/4885MERTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.